EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY 4.0

Renal function and adverse clinical events in anticoagulated patients with atrial fibrillation: insights from the GLORIA-AF Registry Phase III

Yang Liu, Steven Ho Man Lam, Giulio Francesco Romiti, Bi Huang, Yang Chen, Tze Fan Chao, Brian Olshansky, Kui Hong, Menno V Huisman, Gregory Y H Lip, GLORIA-AF Investigators

Journal of Thrombosis and Thrombolysis · 2025

DOI: 10.1007/s11239-025-03067-5 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Thrombosis and Thrombolysis, 2025. Verfasst von Yang Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverp…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Anticoagulants, Kidney. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim GmbH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Renal function, assessed by creatinine clearance (CrCl), affects the efficacy and safety of oral anticoagulant (OAC) therapy in patients with atrial fibrillation (AF). To investigate the association between CrCl and the risk of clinical adverse events and compare the safety profiles of vitamin K antagonists (VKA) and non-vitamin K antagonist oral anticoagulants (NOAC). Patients with newly diagnosed AF (< 3 months before baseline visit) were collected from the prospective Global Registry on Long-Term Oral Anti-Thrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry Phase III. Clinical events assessed included the composite outcome (all-cause death, thromboembolism, and major bleeding), cardiovascular (CV) death, myocardial infarction (MI), and other single outcomes. 10,594 AF patients (mean age 70.35 ± 9.92 years; 55% male; 73% on NOAC) were included. Increasing CrCl was associated with decreased risks of all cause death, composite outcomes and CV-death with in patients with CrCl < 80 mL/min. Multivariate Cox models indicated that compared to VKA, NOAC was associated with lower risks of all cause death (adjusted hazard ratio [aHR] 0.68, 95% CI 0.58–0.78), composite outcomes (aHR 0.77, 95% CI 0.69–0.86), CV-death (aHR 0.70, 95% CI 0.56–0.87), and major bleeding (aHR 0.74, 95% CI 0.61–0.91) in AF patients. For CrCl < 30 mL/min, lower risks of all-cause death, composite outcomes and CV death were related to NOAC therapy. In this large prospective global registry, NOACs were associated with better outcomes compared with VKA for patients with normal or impaired renal function. Graphical abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationAnticoagulantsKidneyHumansMaleFemaleAgedRegistriesMiddle AgedHemorrhageProspective StudiesCreatinineAdministration, OralThromboembolismVitamin K

Stichwörter der Autor:innen

Atrial fibrillationNon-vitamin K antagonist oral anticoagulants (NOACs)Oral anticoagulantRenal functionVitamin K antagonists (VKA)

Substanzen

AnticoagulantsCreatinineVitamin K

Autor:innen und Institutionen

  • Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK.
  • Department of Cardiovascular Medicine, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
  • Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
  • Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Institute of Clinical Medicine, and Cardiovascular Research Center, National Yang-Ming University, Taipei, Taiwan.

Förderung

  • Boehringer Ingelheim GmbH

Zitieren

APA

Liu, Y., Lam, S. H. M., Romiti, G. F., Huang, B., Chen, Y., Chao, T. F., Olshansky, B., Hong, K., Huisman, M. V., Lip, G. Y. H., & GLORIA-AF Investigators (2025). Renal function and adverse clinical events in anticoagulated patients with atrial fibrillation: insights from the GLORIA-AF Registry Phase III. Journal of Thrombosis and Thrombolysis. https://doi.org/10.1007/s11239-025-03067-5

Vancouver

Liu Y, Lam SHM, Romiti GF, Huang B, Chen Y, Chao TF, et al. Renal function and adverse clinical events in anticoagulated patients with atrial fibrillation: insights from the GLORIA-AF Registry Phase III. Journal of Thrombosis and Thrombolysis. 2025. doi:10.1007/s11239-025-03067-5

BibTeX
@article{Liu2025,
  author = {Liu, Yang and Lam, Steven Ho Man and Romiti, Giulio Francesco and Huang, Bi and Chen, Yang and Chao, Tze Fan and Olshansky, Brian and Hong, Kui and Huisman, Menno V and Lip, Gregory Y H and GLORIA-AF Investigators, GLORIA-AF Investigators},
  title = {Renal function and adverse clinical events in anticoagulated patients with atrial fibrillation: insights from the GLORIA-AF Registry Phase III},
  journal = {Journal of Thrombosis and Thrombolysis},
  year = {2025},
  doi = {10.1007/s11239-025-03067-5}
}
Kostenlos starten →